ERBB2 and breast carcinoma: Tumour exosomes can also specifically bind and sequester therapeutic monoclonal antibodies (mAbs) thereby preventing binding of the mAb to the tumour cells and the expected downstream cytotoxicity by immune effector cells, as seen for HER2+ breast cancer cell lines treated with trastuzumab (Herceptin) [166].